Literature DB >> 17376027

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

Marco Conti1, Joseph Beavo.   

Abstract

Although cyclic nucleotide phosphodiesterases (PDEs) were described soon after the discovery of cAMP, their complexity and functions in signaling is only recently beginning to become fully realized. We now know that at least 100 different PDE proteins degrade cAMP and cGMP in eukaryotes. A complex PDE gene organization and a large number of PDE splicing variants serve to fine-tune cyclic nucleotide signals and contribute to specificity in signaling. Here we review some of the major concepts related to our understanding of PDE function and regulation including: (a) the structure of catalytic and regulatory domains and arrangement in holoenzymes; (b) PDE integration into signaling complexes; (c) the nature and function of negative and positive feedback circuits that have been conserved in PDEs from prokaryotes to human; (d) the emerging association of mutant PDE alleles with inherited diseases; and (e) the role of PDEs in generating subcellular signaling compartments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376027     DOI: 10.1146/annurev.biochem.76.060305.150444

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  456 in total

1.  Phosphodiesterases catalyze hydrolysis of cAMP-bound to regulatory subunit of protein kinase A and mediate signal termination.

Authors:  Balakrishnan Shenbaga Moorthy; Yunfeng Gao; Ganesh S Anand
Journal:  Mol Cell Proteomics       Date:  2010-10-05       Impact factor: 5.911

2.  Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.

Authors:  Najma Begum; Steven Hockman; Vincent C Manganiello
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

Review 3.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.

Authors:  Karyn B Cahill; Jonathan H Quade; Karen L Carleton; Rick H Cote
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

5.  IL-1β suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury.

Authors:  Shiqin Xiong; Zhigang Hong; Long Shuang Huang; Yoshikazu Tsukasaki; Saroj Nepal; Anke Di; Ming Zhong; Wei Wu; Zhiming Ye; Xiaopei Gao; Gadiparthi N Rao; Dolly Mehta; Jalees Rehman; Asrar B Malik
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

6.  Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.

Authors:  Ana Santos de Medeiros; Arlene R Wyman; Manal A Alaamery; Christina Allain; F Douglas Ivey; Lili Wang; Hai Le; James P Morken; Alawi Habara; Cuong Le; Shuaiying Cui; Adam Lerner; Charles S Hoffman
Journal:  Cell Signal       Date:  2017-09-01       Impact factor: 4.315

7.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

8.  A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

Authors:  Xian-Feng Huang; Wen-Tao Jiang; Li Liu; Fang-Chen Song; Xia Zhu; Gui-Lan Shi; Shu-Ming Ding; Heng-Ming Ke; Wei Wang; James M O'Donnell; Han-Ting Zhang; Hai-Bin Luo; Yi-Qian Wan; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

Review 9.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

10.  Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders.

Authors:  Jose A Morales-Garcia; Valle Palomo; Miriam Redondo; Sandra Alonso-Gil; Carmen Gil; Ana Martinez; Ana Perez-Castillo
Journal:  ACS Chem Neurosci       Date:  2014-01-17       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.